ARS Pharmaceuticals公司宣布，其研发的Neffy® 1毫克剂量肾上腺素鼻喷雾剂已获得美国食品药品监督管理局（FDA）批准，将取消药品标签中的年龄使用限制。这一重要监管突破意味着该鼻喷雾剂未来可适用于更广泛的年龄群体，为不同年龄段患者提供更便捷的严重过敏反应应急治疗方案。
此次标签变更标志着鼻腔给药技术的临床应用迈出关键一步。与传统注射式肾上腺素相比，鼻喷雾剂具备操作简便、无针头恐惧等优势，尤其适合儿童及特殊需求人群。FDA的批准决定基于临床试验数据，证实该药品在不同年龄层患者中均能实现快速有效的血浆肾上腺素浓度提升。
移除年龄限制不仅拓宽了Neffy®的适用人群，更凸显了ARS Pharmaceuticals在创新给药系统研发领域的技术实力。业界分析指出，此项监管进展可能重塑严重过敏反应应急治疗市场格局，为患者提供更具包容性的医疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.